SCHEMBL30474111

SCHEMBL30474111

Cc1cc(=O)[nH]c2cnccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 5/20 0.67
TNKS2 Q9H2K2 3/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2C19 P33261 1/20 0.56
KDM4E B2RXH2 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
TP53 P04637 1/20 0.51
GLA P06280 1/20 0.51
GAA P10253 1/20 0.51
ADORA3 P0DMS8 2/20 0.50
PARP1 P09874 1/20 0.50
LMNA P02545 1/20 0.47
CHUK O15111 4/20 0.47
GABRP O00591 1/20 0.47
GABRD O14764 1/20 0.47
IKBKB O14920 1/20 0.47
AURKA O14965 1/20 0.47
PIM1 P11309 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19984551 1.00 KDM5A (0.67) KDM5ATNKS2CYP1A2CYP2C19KDM4E
SCHEMBL29498328 0.85 TNKS2 (0.56) KDM5ATNKS2CYP1A2CYP2C19KDM4E
SCHEMBL246359 0.80 KDM5A (0.65) KDM5AKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL4756721 0.80 KDM5A (0.65) KDM5AKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL30064094 0.80 KDM5A (1.00) KDM5AKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL3242090 0.80 KDM5A (1.00) KDM5AKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL9733532 0.76 CYP1A2 (0.58) KDM5ACYP1A2KDM4ESMN1; SMN2ALDH1A1
SCHEMBL14494459 0.76 PDE3B (0.49) KDM5ATNKS2CYP1A2CYP2C19KDM4E
SCHEMBL26347775 0.75 KDM5A (0.62) KDM5AKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL31338639 0.73 PARP1 (0.49) KDM5AKDM4ESMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) 2025-04-03 US disclosed
CN-119343339-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 CN disclosed
EP-4469444-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-04 EP disclosed
WO-2023138684-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO , INC. (US) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR KDM5A 3580/4885TNKS2 4009/4885CYP1A2 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.